0 likes | 11 Views
Oxervate, an FDA-approved eye drop for neurotrophic keratitis, is linked to severe side effects like blindness. Patients are seeking legal compensation, alleging inadequate warnings from the manufacturer, Dompu00e9. Learn more about the Oxervate lawsuits in the article.
E N D
Neurotrophic keratitis is a rare degenerative eye disease that affects the cornea, the clear front part of the eye. • It occurs when the cornea loses sensation due to damaged nerves, leading to ulcers and potentially blindness.
Oxervate, a prescription eye drop developed by the Italian company Dompé farmaceutici S.p.A. • Approved by the FDA in 2018, Oxervate contains cenegermin, a nerve growth factor designed to regenerate damaged corneal nerves.
Recent findings from the FDA's adverse event reporting system highlight serious side effects associated with Oxervate. • Between 2018 and 2022, there were 3,288 reported ocular adverse events, including severe conditions like corneal perforation and eye infections.
These alarming reports have led some patients to consider legal action. • Lawyers are investigating claims that Dompé failed to adequately warn users about the risks of corneal ulcers and deposits.
If you or a loved one has experienced severe side effects from Oxervate, you might be entitled to compensation. • Seek legal advice to understand your rights.
Are you affected? To file a Oxervate Lawsuit, find a attorney experienced in product liability cases. To know More Visit https://medlegal360.com/